Skip to content

艾沃鲁斯

US · EOLS #3736 按市值排名 上市于 2018
7.10 -0.47 -6.21%
实时 - 追踪5344个代码 - 心跳于42秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

增持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例上升了4.1个百分点。

机构持股

机构持股比例
77.33% +4.14pp
机构数量
184 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Hedge Fund35.22%
Mutual Fund31.10%
Individual/Insider10.89%
VC/PE Fund7.71%
Public Company2.13%
Private Company0.65%
Government Pension Fund0.19%
Insurance Company0.15%
Family Office/Trust0.11%
Other11.84%

主要股东 截至 2025-12-31

Timothy Lynch 9.73% · 6.43M 股
Nantahala Capital Management, LLC 8.48% · 5.60M 股
BlackRock 7.33% · 4.84M 股
Soleus Capital Management, L.P. 5.27% · 3.48M 股
Braidwell LP 4.78% · 3.16M 股
Vanguard Capital Management, LLC 4.27% · 2.82M 股
Frazier Life Sciences Management, LP 3.98% · 2.63M 股
Perceptive Advisors LLC 3.72% · 2.46M 股
Millennium Management LLC 2.71% · 1.79M 股
State Street Global Advisors 2.57% · 1.70M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 28次买入 · 22次卖出

姓名职务持股比例
Rui Avelar Chief Medical Officer and Head of Research & Development 0.41%
Vikram Malik Chairperson 0.37%
Brady Stewart Independent Director 0.13%
Sandra Beaver Chief Financial Officer 0.08%
David Gill Independent Director 0.06%
Albert White Independent Director 0.06%
Karah Parschauer Independent Director 0.05%
David Moatazedi Chief Executive Officer 0.00%
Simone Blank Director --
Tomoko Yamagishi-Dressler Chief Marketing Officer --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-01 David Moatazedi Chief Executive Officer Open Market Disposition -105,108 $9.04
2026-03-19 Rui Avelar Chief Medical Officer and Head of Research & Development Automatic Disposition -3,119 $4.75
2026-03-19 David Moatazedi Chief Executive Officer Automatic Disposition -13,669 $4.75
2026-03-16 Rui Avelar Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -8,804 $4.89
2026-03-16 Rui Avelar Chief Medical Officer and Head of Research & Development Automatic Disposition -21,192 $4.89
2026-03-16 David Moatazedi Chief Executive Officer Derivative Exercise and Sale -67,489 $4.89
2026-03-16 David Moatazedi Chief Executive Officer Automatic Disposition -49,231 $4.89
2026-02-16 David Gill Independent Director Other Acquisition +45,559 --
2026-02-16 Rui Avelar Chief Medical Officer and Head of Research & Development Other Acquisition +94,913 --
2026-02-16 Rui Avelar Chief Medical Officer and Head of Research & Development Other Derivative Acquisition +94,913 --
2026-02-16 Rui Avelar Chief Medical Officer and Head of Research & Development Other Derivative Acquisition +138,649 $4.39
2026-02-16 Albert White Independent Director Other Acquisition +45,559 --
2026-02-16 Vikram Malik Chairperson Other Acquisition +45,559 --
2026-02-16 Karah Parschauer Independent Director Other Acquisition +45,559 --
2026-02-16 David Moatazedi Chief Executive Officer Other Acquisition +313,212 --
2026-02-16 David Moatazedi Chief Executive Officer Other Derivative Acquisition +457,541 $4.39
2026-02-16 David Moatazedi Chief Executive Officer Other Derivative Acquisition +626,424 --
2026-02-16 Brady Stewart Independent Director Other Acquisition +45,559 --
2026-02-16 Tatjana Mitchell Chief Financial Officer Other Acquisition +121,489 --
2026-02-16 Tatjana Mitchell Chief Financial Officer Other Derivative Acquisition +121,489 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

艾沃鲁斯 讨论区 0 条评论

发表评论